Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.

Clinical and translational science - 1 Mar 2024

Wanika Linda, Evans Neil D, Johnson Martin, Tomkinson Helen, Chappell Michael J

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events remains unclear. There are limited in vivo studies which focus on TKIs and their effects on different regulation pathways. Many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38477045
DOI: 10.1111/cts.13714
PMCID: PMC10933606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.PMID 38477045Read ↗

Quantitatively Correlating interactions between three intrinsic kinetic processes to in vivo protein kinase occupancySemantic proximity Read ↗

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read ↗

Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions between Tyrosine Kinase Inhibitors and Cardiovascular DrugsSemantic proximity Read ↗

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS- 115 in patients with solid tumorsSemantic proximity Read ↗

Pharmacokinetics of crizotinib in NSCLC patients.Semantic proximity Read ↗

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.Semantic proximity Read ↗

Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity Read ↗

Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN ExpressionSemantic proximity Read ↗

Are improper kinetic models hampering drug development?Semantic proximity Read ↗

Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.